Humacyte Sets Stage for Global Expansion with Strong Q4 2025 Results
Humacyte, a leader in bioengineered vessel technologies, has announced strong fourth quarter and full year 2025 results, setting the stage for global expansion of its flagship product Symvess. In a conference call on March 27, 2026, Humacyte's President and Chief Executive Officer Dr. Laura Niklason highlighted the company's progress in commercializing Symvess, as well as advancing other bioengineered vessel programs.
According to Dr. Niklason, the U.S. Department of Defense has dedicated funding for evaluation and incorporation of new biologic vascular repair technologies, recognizing the need for human-derived bioengineered blood vessels to save life and limb in the battlefield. This historic first-of-its-kind federal investment will help ensure that American service personnel have access to cutting-edge treatments and state-of-the-art care wherever and whenever they need it.
Internationally, interest in Symvess has been highlighted by two recent announcements. Humacyte received a $1.475 million purchase commitment that will facilitate the clinical evaluation and outreach program in hospitals within the Kingdom of Saudi Arabia. Additionally, the company submitted a marketing authorization application with the Israeli Ministry of Health for Symvess for arterial trauma repair.
Commercial adoption of Symvess was further supported by publication of several important papers, including long-term safety data from Humacyte's V005 phase II/III trial in the Journal of Vascular Surgery Cases, Innovations and Techniques. These data were also presented last January by Dr. Michael Curry of the New Jersey Medical School at the annual winter meeting of the Vascular and Endovascular Surgery Society.
Dr. Niklason emphasized that Humacyte's commercial program for Symvess has continued to execute well in the U.S., with a total of 27 VAC approvals to date, as well as an additional 43 VAC committees currently conducting their review process. The company's rate of success with VAC submissions is roughly 70%, and 27 hospitals have ordered Symvess, with the majority placing reorders.
Fourth quarter product sales were $0.4 million for the quarter and $1.4 million for the year. Dr. Niklason noted that these numbers reflect the company's continued investment in commercializing Symvess, as well as advancing other bioengineered vessel programs.
Humacyte's President and Chief Executive Officer Dr. Laura Niklason stated, "Our fourth quarter and recent weeks have been a productive period for Humacyte, with continued execution of our commercial program for Symvess and the advancement of other bioengineered vessel programs." Dale Sander, Chief Financial Officer and Chief Development Officer added that the company's financial results for the year reflect its ongoing commitment to advancing this groundbreaking technology.
